Synthesis of 2′-Deoxy-2′-[18F]Fluoro-9-β-D-Arabinofuranosylguanine: a Novel Agent for Imaging T-Cell Activation with PET
9-(β-D-Arabinofuranosyl)guanine (AraG) is a guanosine analog that has a proven efficacy in the treatment of T-cell lymphoblastic disease. To test the possibility of using a radiofluorinated AraG as an imaging agent, we have synthesized 2′-deoxy-2′-[18F]fluoro-9-β-D-arabinofuranosylguanine ([18F]F-AraG) and investigated its uptake in T cells.
We have synthesized [18F]F-AraG via a direct fluorination of 2-N-acetyl-6-O-((4-nitrophenyl)ethyl)-9-(3′,5′-di-O-trityl-2′-O-trifyl-β-D-ribofuranosyl)guanine with [18F]KF/K.2.2.2 in DMSO at 85°C for 45 min. [18F]F-AraG uptake in both a CCRF-CEM leukemia cell line (unactivated) and activated primary thymocytes was evaluated.
We have successfully prepared [18F]F-AraG in 7–10% radiochemical yield (decay corrected) with a specific activity of 0.8–1.3 Ci/μmol. Preliminary cell uptake experiments showed that both a CCRF-CEM leukemia cell line and activated primary thymocytes take up the [18F]F-AraG.
For the first time to the best of our knowledge, [18F]F-AraG has been successfully synthesized by direct fluorination of an appropriate precursor of a guanosine nucleoside. This approach maybe also useful for the synthesis of other important positron emission tomography (PET) probes such as [18F]FEAU, [18F]FMAU, and [18F]FBAU which are currently synthesized by multiple steps and involve lengthy purification. The cell uptake studies support future studies to investigate the use of [18F]F-AraG as a PET imaging agent of T cells.
Key wordsImaging T cells 9-(β-D-Arabinofuranosyl) guanine (AraG) Positron emission tomography (PET)
- 8.Hitchcock MJ, Woods K, DeBoeck H, Ho HT (1990) Biochemical pharmacology of 2-flouro-2′, 3′-dideoxyarabinofuranosyladenine, an inhibitor of HIV with improved metabolic and chemical stability over 2′, 3′-dideoxyadenosine. Antiviral Chem Chemother 1:319–327Google Scholar
- 9.Silverman RB (1988) In mechanism-based enzyme inactivation: chemistry and enzymology, vol 1. CRC, Boca Raton, p 59Google Scholar
- 13.Kurtzberg J, Ernst TJ, keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Kerenitsky T, Elion G, Mitchell BS (2005) Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 23:3396–3403PubMedCrossRefGoogle Scholar
- 16.Lyer M, Barrio JR, Namavari M, Bauer E, Satyamurthy N, Nguyen K, Toyokuni T, Phelps ME, Herschman HR, Gambhir SS (2001) 8-[18F]Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET. J Nucl Med 42:96–105Google Scholar
- 24.Chu CK, Matulic-Aamic J, Huang JT, Chou TC, Bruchenal JH, Fox JJ, Watanabe KA (1989) Synthesis of 9-(-2-Deoxy-2-fluoro-b-d-arabinofuranosy)-9-H-purines and their biological activites. Chem Pharm Bull 37:336–339Google Scholar
- 26.Cooper TM (2007) Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manage 3(6):1135–1141Google Scholar